Second‑Line Antiepileptic Options for Status Epilepticus in Patients Allergic to Levetiracetam

Acute Seizure Management (Status Epilepticus)

After benzodiazepine failure, intravenous valproate is recommended as a Level B second‑line agent for refractory status epilepticus (American College of Emergency Physicians guideline) 1, 2.
Valproate dosing: loading dose 20–30 mg/kg IV administered at 40 mg/min; this regimen achieves rapid therapeutic levels 3, 2.
Alternative second‑line agents are phenytoin (18–20 mg/kg IV) or fosphenytoin (18–20 PE/kg IV); both are associated with higher rates of adverse effects compared with valproate 1, 2.
Efficacy and safety (Class II studies): valproate achieved seizure control in 79 % of patients versus 25 % with phenytoin (absolute risk reduction = 54 %); hypotension occurred in 0 % with valproate versus 12 % with phenytoin 4, 5.

Carbamazepine is the first‑line monotherapy for focal‑onset seizures in adults and children (International League Against Epilepsy recommendation) 6, 7.
Phenytoin or phenobarbital may be used when cost constraints limit other options 6, 7.

Valproic acid (sodium valproate) remains the first‑line treatment for generalized tonic‑clonic seizures 6, 7.
Contraindication: valproic acid should be avoided in women of child‑bearing potential unless strict contraceptive measures or special risk‑benefit considerations are in place 7, 8.
Alternative for women: carbamazepine can be used, though it is less effective than valproate for generalized seizures 7.

Drug	Loading Dose	Maintenance	Key Adverse Effects
Valproate (Depacon)	20–30 mg/kg IV at 40 mg/min	1–2 mg/kg/h IV after loading	Dizziness, thrombocytopenia, hepatotoxicity, hyperammonemia [3]
Phenytoin	18–20 mg/kg IV	–	Hypotension, cardiac dysrhythmias, soft‑tissue injury, purple‑glove syndrome [3]
Fosphenytoin	18–20 PE/kg IV	–	Same as phenytoin; less local irritation [3]
Phenobarbital	10–20 mg/kg IV (may repeat 5–10 mg/kg after 10 min)	1–3 mg/kg IV every 12 h	Respiratory depression, hypotension [3]

Delay in administering a second‑line agent after benzodiazepine failure leads to poorer outcomes; agents should be given immediately 2, 5.
Underdosing the loading dose is linked to treatment failure; the full recommended dose must be delivered 2.
Phenytoin infusion rate must not exceed 50 mg/min to avoid cardiac complications 4.
In women of child‑bearing age, teratogenic risk of valproate must be assessed and contraception status confirmed before use 7, 8.

Administration speed: valproate can be infused at 40 mg/min, faster than the 50 mg/min limit for phenytoin, facilitating quicker seizure control 4.
Hypotension: incidence is 0 % with valproate versus 12 % with phenytoin 3.
Local tissue injury: valproate carries no risk of soft‑tissue injury or purple‑glove syndrome, unlike phenytoin 3.
Efficacy: seizure cessation achieved in 88 % of patients with valproate versus 84 % with phenytoin 4.

Level A evidence supports the addition of a second antiepileptic medication after benzodiazepine‑refractory status epilepticus 1, 2.
Level B evidence indicates that valproate, phenytoin, or fosphenytoin may be used as second‑line agents in this setting 1, 2.
Class II studies demonstrate valproate’s superior tolerability and safety profile compared with phenytoin 4, 5.